Who Owns Bio-Techne Company?

Bio-Techne Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Bio-Techne Corporation?

Understanding corporate ownership is key to grasping a company's strategy and market impact. For Bio-Techne, a leader in the life sciences sector, knowing its ownership structure is vital for investors and stakeholders alike. Recent actions, like a significant share repurchase program announced in May 2025, highlight the dynamic interplay between management, board decisions, and shareholder value.

Bio-Techne Corporation, established in 1976, has evolved significantly since its inception. Its journey from a private entity to a publicly traded global supplier of life science reagents and instruments reflects a strategic growth path influenced by its ownership evolution.

As of August 15, 2025, Bio-Techne Corporation, with a market capitalization of approximately $8.40 billion, is primarily owned by institutional investors, who hold a substantial portion of its shares. These institutions, such as investment management firms and mutual funds, play a significant role in shaping the company's direction through their investment decisions and voting power. Public shareholders, including individual investors, also contribute to the ownership structure, with their collective holdings representing a smaller but still important segment. The company's commitment to innovation is evident in its diverse product offerings, including those detailed in the Bio-Techne PESTEL Analysis. For fiscal year 2024, Bio-Techne reported net sales of approximately $1.2 billion, demonstrating its robust financial performance and market presence.

Bio-Techne's journey began in 1976 with the establishment of Research and Diagnostic Systems, Inc. in Minneapolis. Roger C. Lucas is widely recognized as the founder, with David Mundschenk also noted as a co-founder. The company's initial focus was on hematology controls, launching its first product in 1977.

Founding of Research and Diagnostic Systems

Research and Diagnostic Systems, Inc. was founded in Minneapolis in 1976. Roger C. Lucas is credited as the founder, with David Mundschenk also recognized for his role.

Initial Product Focus

The company's early operations centered on the production of hematology controls. Its inaugural product, a Platelet-Rich-Plasma control, was introduced in 1977.

Early Ownership Details

Specific details regarding the initial equity distribution among the founders are not readily available from the early period. However, founder agreements like vesting schedules were likely in place.

Transition to Public Ownership

A pivotal moment occurred in 1985 when Research and Diagnostic Systems, Inc. merged into Techne Corporation. This merger transformed the company into a publicly traded entity.

IPO and Broader Investment

Techne Corporation had previously completed an IPO as a blind pool in 1983. The 1985 merger marked the formal inclusion of public shareholders, broadening the ownership base.

Strategic Shift

This transition to a public company under Techne Corporation facilitated greater access to capital. It represented a strategic move that gradually shifted control from the founders to a wider shareholder base.

The merger with Techne Corporation in 1985 was a significant event, transitioning the company from a privately held, founder-controlled business to a publicly traded entity. This move opened avenues for broader capital access and fundamentally altered the Bio-Techne company structure, paving the way for wider Bio-Techne stock ownership. While specific early angel investors are not extensively documented, the public listing initiated a new phase of Bio-Techne ownership involving a diverse group of shareholders. This strategic shift was crucial for the company's future growth and expansion, as detailed in its Growth Strategy of Bio-Techne.

Key Milestones in Early Ownership

The early history of Bio-Techne ownership is marked by key transitions from private founding to public trading.

• Founding of Research and Diagnostic Systems, Inc. in 1976 by Roger C. Lucas and David Mundschenk.
• Introduction of the first product, a Platelet-Rich-Plasma control, in 1977.
• Merger with Techne Corporation in 1985, leading to public trading.
• Techne Corporation's IPO as a blind pool in 1983.
• Shift from founder control to a broader public shareholder base.

Bio-Techne SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership journey of Bio-Techne, originally known as Techne Corporation following its 1983 IPO as a blind pool, has been shaped by strategic acquisitions and evolving major shareholdings. As of August 15, 2025, the company's market capitalization reached approximately $8.40 billion, with 156.77 million shares outstanding, a figure influenced by a four-for-one stock split on November 29, 2022.

The current ownership landscape of Bio-Techne is heavily dominated by institutional investors, who collectively hold 98.95% of the company's stock as of August 2025. Insiders represent a smaller portion, with 1.08% ownership. This concentration of shares among large asset managers, such as BlackRock, Inc., T. Rowe Price Associates Inc., Charles Schwab Investment Management Inc., and Vanguard Fiduciary Trust Co., signifies a broad ownership structure where these entities wield considerable influence over corporate strategy and governance through their voting and dispositive powers. Understanding these Bio-Techne shareholders is key to grasping the company's direction and its Competitors Landscape of Bio-Techne.

Key Ownership Insights

Institutional investors are the primary owners of Bio-Techne, reflecting a common trend in publicly traded companies.

• Institutional investors own 98.95% of Bio-Techne stock.
• Insiders hold 1.08% of the company's shares.
• BlackRock, Inc. is a major stakeholder with sole voting power.
• T. Rowe Price Associates Inc. holds a significant stake and voting power.
• Charles Schwab Investment Management Inc. increased its stake in Q1 2025.

Bio-Techne PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Bio-Techne provides critical oversight and strategic direction, with recent adjustments to committee assignments. Kim Kelderman is the current President and Chief Executive Officer, having taken over from Chuck Kummeth. Robert V. Baumgartner serves as Chairman of the Board.

Directors are elected annually through a majority vote, adhering to a 'one-share-one-vote' principle. This structure ensures that voting power is distributed based on share ownership, without preferential voting rights. As of August 2025, institutional investors hold a substantial 98.95% of the company's stock, indicating that these entities collectively wield significant influence over corporate decisions through their voting power and engagement with the board. The board's composition is designed to include individuals with diverse backgrounds, particularly those with strong scientific and executive experience, to bolster its oversight capabilities.

Understanding Bio-Techne's Corporate Governance

Bio-Techne's corporate governance framework is detailed in its SEC filings, providing transparency for investors. The company's structure emphasizes shareholder rights and board accountability.

• Directors are elected annually by a majority of votes cast.
• The 'one-share-one-vote' system ensures equal voting power per share.
• Institutional ownership stands at 98.95% as of August 2025.
• The board aims for a balance of scientific and executive expertise.
• Recent proxy statements, like the one filed September 12, 2024, offer insights into board composition and voting matters.

Bio-Techne Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past three to five years, Bio-Techne's ownership profile has seen significant shifts, marked by strategic capital allocation and leadership changes. The company's commitment to its shareholders is evident through substantial share repurchase programs and consistent dividend payouts, reinforcing its stable ownership trends.

The ownership landscape of Bio-Techne remains dominated by institutional investors, who held nearly 99% of the company's stock as of August 2025. This high level of institutional Bio-Techne stock ownership suggests that major investors and funds play a significant role in shaping the company's corporate governance and strategic decisions. These Bio-Techne major investors, through their substantial stakes, influence the company's direction and capital allocation strategies, as highlighted by recent developments such as the new $500 million share repurchase program and the divestiture of its Exosome Diagnostics business.

Shareholder Returns

Bio-Techne's commitment to shareholder value is underscored by its $500 million share repurchase program and consistent dividend payments, reflecting confidence in future performance.

Strategic Portfolio Adjustments

The company is actively managing its portfolio through acquisitions like Lunaphore and divestitures such as Exosome Diagnostics, aiming to optimize its market position.

Leadership Evolution

The recent appointment of Kim Kelderman as CEO signifies a new chapter in leadership, impacting the company's strategic vision and operational execution.

Institutional Dominance

With institutional investors holding nearly 99% of the stock, their influence on Bio-Techne's corporate governance and strategic direction is paramount.

Bio-Techne Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔